Interim financial report 4 for the period 1st of June – 31st of August and the report for the full fiscal year

Wed, Oct 24, 2018 08:30 CET

CELLINK AB ("CELLINK" or "Company") publishes the quarterly report for the period 1st of June 2018 – 31st of August 2018 and the report for the full fiscal year. The report is available on the company's website: http://cellink.com/investor-relations/. This press release presents a summary of the report.

Interim Financial Report 12 months, 1 September 2017 – 31 August 2018

Net turnover of SEK 45,337 thousand (SEK 13,159 thousand), an increase of 245% against the previous accounting year
Operating revenues, including capitalized work for own account and changes in inventory, amounted to SEK 64,444 thousand (SEK 21,876 thousand), an increase of 196% against the previous accounting year
Operating profit before depreciation, EBITDA amounted to SEK 2,997 thousand, which corresponds to an EBITDA margin of 4.7% (-2%)
Operating profit summed up to SEK 372 thousand (SEK -887 thousand)
Profit before tax amounted to SEK 1,068 thousand (SEK -728 thousand)
Earnings per share amounted to SEK 0.15 (SEK -0.12)
Cash flow from ongoing activities amounted to SEK -12,263 thousand (SEK -1,491 thousand)

Quarter 4 (Q4), 1 June 2018 – 31 August 2018

Net turnover of SEK 16,465 thousand (SEK 4,711 thousand), an increase of 250% against the fourth quarter in the previous fiscal year
Operating revenues, including capitalized work for own account and changes in inventory, amounted to SEK 23,132 thousand (SEK 8,444 thousand), an increase of 174% against the fourth quarter in previous fiscal year
Operating profit before depreciation, EBITDA, amounted to SEK 1,069 thousand, which corresponds to an EBITDA margin of 4.6% (0.3%)
Operating profit summed up to SEK 402 thousand (SEK -216 thousand)
Profit before tax amounted to SEK 596 thousand (SEK 43 thousand)
Profit per share amounted to SEK 0.07 in the quarter (SEK 0.02)
Cash flow from ongoing activities amounted to SEK -7,085 thousand (SEK – 1,124 thousand)

Significant events during the period (June 2018 – August 2018)

On 1 June CELLINK published news on the ground-breaking 3D-bioprinting of the first human corneas by CELLINK customer and technology users at Newcastle University
On 4 June CELLINK completed a targeted new share issue of SEK 100,259,570
On 4 July CELLINK published research achievements involving the company´s ink
On 16 July the company announced that they have been granted project funding of SEK 25 million from EU
On 27 August CELLINK launched new bioink based on laminins

Events after the closing date (31st of August)

On 4 September CELLINK published three new research achievements made with the company´s products
On 11 September the company announced that Dr. Mina Bisell enters CELLINKS Advisory Board
On 2 October the company announced they have been granted project funding of SEK 3 million from EU

Events during the fiscal year (September 2017 – August 2018)

On 25 September CELLINK was awarded a registered design patent for its product BIO X
On 27 September CELLINK announced a collaboration agreement with the Massachusetts Institute of Technology
On 6 October a targeted new share issue of SEK 30 million was made to Handelsbanken Funds
On 15 November CELLINK announced a collaboration on development with Takara Bio
On 27 November the company advised that it had been granted project funding from the EU of SEK 3.5 million.
On 8 January the company announced a collaboration agreement with CTIBIOTECH to print human cancer tumour tissues
On 17 January the company announced its establishment of a research and development laboratory in AstraZeneca’s BioVentureHub
On 1 February CELLINK advised it would be opening an office at Kyoto University in Japan
On 8 February CELLINK advised it would be launching CELLINK X Bioinks
On 19 March CELLINK published an article on bioink together with researchers, the article was published in Bioprinting and dealt with the different features of bioink
On 9 April CELLINK won the Red Dot Award for BIO X
On 13 April CELLINK launched 7 new bioinks, 3 new kits of GelMA and enabled the 3D bioprinting of multifaceted vascular networks
On 19 April CELLINK entered into a partnership with ARMI BioFab USA, and the UNH Manchester for events dealing with regenerative production
On 23 April CELLINK appointed Carnegie Investment Bank AB (publ) as its financial advisor
On 2 May CELLINK launched a new pedagogic platform for bioprinting: CELLINK GO – developed to revolutionise education
On 3 May CELLINK changed its Certified Adviser to Erik Penser Bank AB
On 4 May CELLINK published news of a cooperating partner that 3D bioprints human heart valve disease models with nanoindentation-based biomechanics
On 11 May CELLINK received an order for SEK 3.5 million from a distributor
On 1 June CELLINK published news on the ground-breaking 3D-bioprinting of the first human corneas by customer and technology users at Newcastle University
On 4 June CELLINK completed a targeted new share issue of SEK 100,259,570
On 4 July CELLINK published research achievements involving the company´s ink
On 16 July the company announced that the company have been granted project funding of SEK 25 million from EU
On 27 August CELLINK launched new bioink based on laminins

For clarity, the official interim report is the Swedish version. This English edition is translated and if there are conflicting information, we refer to the Swedish version.

For further information, please contact:

Erik Gatenholm, CEO Gusten Danielsson, CFO

Phone: +46 73 267 00 00 Phone: +46 70 991 86 04

E-mail: eg@cellink.com E-mail: gd@cellink.com

Important information

This information is such information as CELLINK AB is required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on October 24, 2018 at. 08:30 CET.

About CELLINK

CELLINK has created one of the world's first universal Bioinks, today used by many of the world's most well-reputed research institutions. A Bioink can be mixed with living cells to print functional human tissues and if future research is successful, eventually, complete human organs in so-called 3D-Bioprinters. CELLINK's universal Bioink shows excellent results and can be used in both CELLINK's proprietary 3D Bioprinters and in 3D Bioprinters developed by other operators. Erik Penser Bank AB is the company's Certified Adviser, available on tel: +46 8 463 80 00. The company is listed on Nasdaq First North under CLNK.

Interim financial report 4 for the period 1st of June – 31st of August and the report for the full fiscal year

Documents & Links